The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Psychotropic Medication Use and Polypharmacy in Children With Autism Spectrum Disorders
Open accessAbstract
OBJECTIVE: The objectives of this study were to examine rates and predictors of psychotropic use and multiclass polypharmacy among commercially insured children with autism spectrum disorders (ASD). METHODS: This retrospective observational study used administrative medical and pharmacy claims data linked with health plan enrollment and sociodemographic information from 2001 to 2009. Children with ASD were identified by using a validated ASD case algorithm. Psychotropic polypharmacy was defined as concurrent medication fills across ≥ 2 classes for at least 30 days. Multinomial logistic regression was used to model 5 categories of psychotropic use and multiclass polypharmacy. RESULTS: Among 33,565 children with ASD, 64% had a filled prescription for at least 1 psychotropic medication, 35% had evidence of psychotropic polypharmacy (≥ 2 classes), and 15% used medications from ≥ 3 classes concurrently. Among children with polypharmacy, the median length of polypharmacy was 346 days. Older children, those who had a psychiatrist visit, and those with evidence of co-occurring conditions (seizures, attention-deficit disorders, anxiety, bipolar disorder, or depression) had higher odds of psychotropic use and/or polypharmacy. CONCLUSIONS: Despite minimal evidence of the effectiveness or appropriateness of multidrug treatment of ASD, psychotropic medications are commonly used, singly and in combination, for ASD and its co-occurring conditions. Our results indicate the need to develop standards of care around the prescription of psychotropic medications to children with ASD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have reported high rates of polypharmacy ranging from 12 to 35% based on the type of studies [28, 29].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [29]
In the citing paper
“This estimate is higher than reports from prior longitudinal studies in solely pediatric populations with ASD.”
From Medication use in the management of comorbidities among individuals with autism spectrum disorder from a large nationwide insurance database (2021) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tabachnick, B. G., & Fidell, L. S. (1983) · Cited by 79,882
Applied Multivariate Statistics for the Social Sciences
Stevens, J. P. (2012) · Routledge eBooks · doi:10.4324/9780203843130 · Cited by 10,652
Applied Multivariate Statistics for the Social Sciences
Schumm, W. R., & Stevens, J. P. (1993) · The American Statistician · doi:10.2307/2685203 · Cited by 1,533
Murray, C. J. L., Kulkarni, S. C., Michaud, C., Tomijima, N., Bulzacchelli, M. T., Iandiorio, T. J., & Ezzati, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030260 · Cited by 762
Freund, R. J., & Littell, R. C. (2000) · Medical Entomology and Zoology · Cited by 525
Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders
Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008) · Pediatrics · doi:10.1542/peds.2007-0984 · Cited by 295
Comer, J. S., Olfson, M., & Mojtabai, R. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.07.007 · Cited by 253
America's Children: Key National Indicators of Well-Being
Blachman, D., & Lukacs, S. L. (2009) · Annals of Epidemiology · doi:10.1016/j.annepidem.2009.07.040 · Cited by 240
Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1013 · Cited by 227
Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children
Olfson, M., Crystal, S., Huang, C., & Gerhard, T. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2009.09.003 · Cited by 211
Research works printed but not linked: 1
- Parr J. Autism. Clin Evid (online). 2010;2010:0322. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC2907623/. Accessed August 2, 2013
Cited by
Sorted by citations
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review
Jobski, K., Höfer, J., Hoffmann, F., & Bachmann, C. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12644 · Cited by 263
Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders
Theoharides, T. C., Tsilioni, I., Patel, A., & Doyle, R. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.77 · Cited by 234
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233
Vohra, R., Madhavan, S., & Sambamoorthi, U. (2016) · Autism · doi:10.1177/1362361316665222 · Cited by 181
Metadata
- Authors
- Spencer, D., Marshall, J., Post, B., Kulakodlu, M., Newschaffer, C., Dennen, T., Azocar, F., & Jain, A.
- Affiliations
- Optum (United States) (US)
- Lewin Group (United States) (US)
- Drexel University (US)
- OptumHealth Behavioral Solutions, San Francisco, California
- Venue
- PEDIATRICS
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2013-11-01
- Volume
- 132
- Issue
- 5
- Pages
- 833-840
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- PMC
- PMC3813388
- OpenAlex
- W2153868538
- Cited by
- 215
- References
- 29
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 17 · 2023: 14 · 2022: 21 · 2021: 24 · 2020: 20 · 2019: 16 · 2018: 17 · 2017: 18 · 2016: 19 · 2015: 17 · 2014: 5
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- PEDIATRICS (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Keywords
- autism spectrum disorder, psychotropic drugs, polypharmacy, children, comorbidities, psychiatric comorbidity, prescribing patterns, standard of care
- MeSH terms
- Adolescent, Child, Child Development Disorders, Pervasive, Child, Preschool, Female, Humans, Infant, Male, Psychotropic Drugs, Retrospective Studies, Polypharmacy, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
